Mabion S.A. (FRA:272)
Germany
· Delayed Price · Currency is EUR 1.624
-0.030 (-1.81%)
Last updated: Dec 5, 2025, 8:18 AM CET
Mabion Revenue
Mabion had revenue of 3.26M PLN in the quarter ending June 30, 2025, a decrease of -89.05%. This brings the company's revenue in the last twelve months to 11.24M, down -91.96% year-over-year. In the year 2024, Mabion had annual revenue of 69.02M, down -54.50%.
Revenue (ttm)
11.24M PLN
Revenue Growth
-91.96%
P/S Ratio
7.85
Revenue / Employee
52.78K PLN
Employees
213
Market Cap
27.24M EUR
Revenue Chart
* This company reports financials in PLN.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Rheinmetall AG | 11.00B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
Mabion News
- 5 years ago - Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer - GlobeNewsWire
- 5 years ago - Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease - GlobeNewsWire
- 6 years ago - GAMCO Investors Exits Viacom, Spark Therapeutics - GuruFocus
- 6 years ago - Regulators Give Roche Green Light For $4.3B Spark Therapeutics Acquisition - Benzinga
- 6 years ago - Roche to complete $4.3 billion Spark deal as regulators give all clear - Reuters
- 6 years ago - U.S. antitrust enforcers give Roche approval to buy Spark Therapeutics - Reuters
- 6 years ago - Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product - GlobeNewsWire
- 6 years ago - FTC staff recommends approval of Roche deal for Spark: report - Reuters